查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1945914

糖尿病酮酸症市场－全球产业规模、份额、趋势、机会及预测（依疗法、最终用户、地区及竞争格局划分，2021-2031年）

Diabetic Ketoacidosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球糖尿病酮酸症市场预计将从 2025 年的 33.7 亿美元成长到 2031 年的 46.8 亿美元，复合年增长率达到 5.63%。

该市场涵盖了治疗这种危及生命的代谢性疾病所需的关键诊断和治疗药物，例如输液疗法、电解质管理方案和静脉注射胰岛素。推动这一市场成长的关键因素是全球糖尿病盛行率的不断上升，这显着增加了面临高血糖紧急情况风险的患者数量。根据国际糖尿病联盟 (IDF) 预测，到 2024 年，全球将有约 5.89 亿成年人患有糖尿病，这一数字凸显了对有效急性护理措施的巨大且日益增长的需求。不断加重的疾病负担，加上现有患者对胰岛素治疗的依从性较低，进一步推动了对这些关键医疗产品的持续需求。

市场概览
预测期 2027-2031
市场规模：2025年 33.7亿美元
市场规模：2031年 46.8亿美元
复合年增长率：2026-2031年 5.63%
成长最快的细分市场 医院和诊所
最大的市场 北美洲

然而，限制整体市场成长的主要障碍是专科治疗方案和重症监护住院治疗的高昂费用。在许多开发中国家，基本诊断工具和先进医疗基础设施的匮乏进一步限制了有效医疗服务的提供。因此，儘管糖尿病发病率的上升为市场扩张奠定了坚实的基础，但中低收入地区医疗资源分配不均和经济障碍仍然是公平获得治疗和全球整体成长的重大阻碍。

市场驱动因素

速效胰岛素疗法的需求不断增长是全球糖尿病酮酸症(DKA) 市场的主要驱动因素。随着高血糖紧急情况发生率的增加，作为 DKA 临床管理核心的强化胰岛素疗法的需求在全球范围内持续增长。主要治疗药物生产商的强劲商业性表现进一步强化了这一趋势，凸显了这些救命药物的重要性。例如，诺和诺德公司于 2025 年 2 月发布的《2024 年年度报告》预测，2024 年胰岛素总销售额将成长 15.3%，显示人们越来越依赖胰岛素产品来应对严重的代谢併发症。

同时，照护现场酮体监测和连续诊断解决方案的技术进步也在推动市场扩张。主动疾病管理的趋势正在加速先进感测器设备的普及，这些设备能够早期检测酮症，从而降低严重住院的风险并改善患者预后。根据雅培公司于2025年1月发布的“2024年第四季度及全年业绩报告”，其糖尿病护理产品销售额在第四季度增长了22.7%，表明新一代监测技术正在被迅速采用。更广泛的行业趋势也进一步支撑了这一强劲领域的成长。礼来公司在2025年1月报告称，由于全球对综合糖尿病护理产品的需求不断增长，其2024年全年全球收入增长了32%。

市场挑战

与特殊治疗方案和重症监护住院相关的巨额经济负担，严重阻碍了全球糖尿病酮酸症市场的扩张。妥善管理这种疾病需要昂贵的医疗资源，包括严格的液体疗法、持续胰岛素输注系统和持续的检查室监测。在资源匮乏的地区，医疗机构缺乏维持这些昂贵通讯协定的预算，导致大多数患者无法获得这些重要的诊断和治疗方法。这种经济差距使得临床需求无法转化为实际效益，阻碍了高疾病负担发展中地区的市场渗透。

这种经济限制因素因糖尿病治疗本身所需的高昂费用而加剧，这对各国医疗预算带来了巨大压力。国际糖尿病联盟报告称，到2024年，全球糖尿病医疗支出将超过1兆美元。如此高昂的支出迫使许多医疗系统重新分配资源，优先考虑基础维护护理而非专科急诊护理。因此，不断上涨的医疗成本阻碍了经济困难市场获得基本医疗产品的途径，直接限制了全球医疗产业的成长。

市场趋势

自动化闭合迴路胰岛素输注系统的普及正在改变全球糖尿病酮酸症市场的预防性治疗模式，其透过自动调整基础胰岛素剂量来预防高血糖危象。与传统的多次注射疗法不同，这些混合闭合迴路设备利用连续血糖数据，透过演算法自动调整或停止胰岛素剂量，在1型和2型糖尿病患者出现酮症之前进行直接干预。这种向自动化预防性治疗的转变正在推动其商业性应用的显着增长。 Insulet公司在2024年11月发布的2024年第三季财报中指出，受其自动化给药平台快速成长的推动，季度营收成长25.7%至5.439亿美元。

此外，将人工智慧 (AI) 应用于预测性血糖分析，能够在代谢补偿发生前数小时识别糖尿病酮酸症(DKA) 的风险因素，从而从根本上改变临床策略。胰岛素管理生态系中的先进演算法分析历史血糖值趋势，预测严重高血糖事件，并发出警报，提示及时进行预防性胰岛素或输液，以稳定患者的生理功能。这种朝向智慧化、数据驱动的疾病管理模式的转变，正在加速智慧糖尿病技术的应用。根据Medtronic于 2024 年 11 月发布的“2025 财年第二季度财务业绩报告”，其糖尿病部门的销售额增长了 12.4%，达到 6.86 亿美元，凸显了市场向算法增强型预测系统的转变。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球糖尿病酮酸症市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依治疗方法（胰岛素治疗、电解质补充、液体补充）
    • 按最终使用者（医院/诊所、门诊护理中心、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

6. 北美糖尿病酮酸症市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲糖尿病酮酸症市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区糖尿病酮酸症市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东和非洲糖尿病酮酸症市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

10. 南美洲糖尿病酮酸症市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球糖尿病酮酸症市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Novo Nordisk AS
  • Baxter Healthcare Corporation
  • B. Braun Medical Inc.
  • ICU Medical, Inc.
  • Pfizer Inc.
  • Merit Pharmaceutical
  • SteriCare Solutions
  • Soxa Formulations & Research（Pvt.）Ltd
  • BD company
  • Fresenius Kabi USA LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 17286

The Global Diabetic Ketoacidosis Market is projected to expand from USD 3.37 Billion in 2025 to USD 4.68 Billion by 2031, achieving a compound annual growth rate of 5.63%. This market covers essential diagnostics and therapeutics, such as fluid replacement therapies, electrolyte management solutions, and intravenous insulin, all of which are vital for treating this life-threatening metabolic condition. A major factor driving this growth is the rising global prevalence of diabetes, which significantly increases the number of patients at risk for hyperglycemic emergencies. According to the International Diabetes Federation, there were roughly 589 million adults living with diabetes globally in 2024, a figure that highlights the substantial and growing need for effective acute care measures. This rising disease burden, combined with frequent insulin non-compliance among existing patients, reinforces the sustained demand for these critical medical products.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.37 Billion
Market Size 2031USD 4.68 Billion
CAGR 2026-20315.63%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Conversely, a major hurdle restricting broader market growth is the substantial expense linked to specialized treatment regimens and intensive care hospitalization. In many developing countries, restricted access to essential diagnostic tools and advanced healthcare infrastructure further limits the effective provision of care. As a result, although the increasing incidence of diabetes provides a solid basis for market expansion, healthcare disparities and financial barriers in low-to-middle-income regions persist as significant obstacles to equitable treatment access and overall global growth.

Market Driver

The escalating need for rapid-acting insulin therapies acts as a primary catalyst for the Global Diabetic Ketoacidosis Market. As hyperglycemic emergencies become more frequent, the demand for intensive insulin regimens-which are central to clinical DKA management-continues to grow worldwide. This trend is reinforced by the strong commercial results of leading therapeutic manufacturers, underscoring the vital importance of these life-saving medications. For instance, Novo Nordisk's 'Annual Report 2024', released in February 2025, revealed that total insulin sales rose by 15.3% in 2024, demonstrating the increasing reliance on essential insulin products to handle severe metabolic complications.

Simultaneously, market expansion is being driven by technological progress in point-of-care ketone monitoring and continuous diagnostic solutions. The transition toward proactive disease management has accelerated the use of advanced sensor-based devices that allow for the early detection of ketosis, thereby lowering the likelihood of severe hospitalization and enhancing patient outcomes. According to Abbott's 'Fourth-Quarter and Full-Year 2024 Results' from January 2025, Diabetes Care sales increased by 22.7% in the fourth quarter, indicating a swift adoption of next-generation monitoring technologies. This strong sector growth is further supported by wider industry trends; Eli Lilly and Company reported in January 2025 that their full-year 2024 worldwide revenue jumped by 32%, fueled by the surging global demand for comprehensive diabetes care products.

Market Challenge

The significant financial strain associated with specialized treatment regimens and intensive care hospitalization poses a major obstacle to the expansion of the Global Diabetic Ketoacidosis Market. Successfully managing this condition requires costly medical resources, such as rigorous fluid resuscitation, continuous insulin delivery systems, and persistent laboratory monitoring. In resource-constrained environments, healthcare facilities often lack the necessary budget to sustain such expensive protocols, making these critical diagnostics and therapeutics unreachable for a vast portion of the patient population. This gap in affordability stops clinical needs from translating into actual revenue, thereby limiting market penetration in developing regions with a high disease burden.

This economic limitation is further intensified by the massive expenditures already required for general diabetes care, which places a heavy strain on national healthcare budgets. As reported by the International Diabetes Federation, global health expenditure related to diabetes exceeded USD 1 trillion in 2024. Such high spending levels compel many healthcare systems to ration resources, often favoring basic maintenance over specialized emergency interventions. Consequently, the high cost of care restricts the uptake of essential medical products in economically challenged markets, directly hindering the overall growth of the global sector.

Market Trends

The uptake of Automated Closed-Loop Insulin Delivery Systems is reshaping the preventive landscape of the Global Diabetic Ketoacidosis Market by automating basal insulin modulation to prevent hyperglycemic crises. Distinct from traditional multiple daily injection therapies, these hybrid closed-loop devices employ continuous glucose data to algorithmically adjust or suspend insulin delivery, thereby intervening directly before the onset of ketosis in Type 1 and Type 2 diabetes patients. This therapeutic transition toward automated preventive care is fueling significant commercial adoption; Insulet Corporation reported in its 'Third Quarter 2024 Financial Results' in November 2024 that quarterly revenue rose by 25.7% to USD 543.9 million, driven by the rapid growth of its automated delivery platform.

Additionally, the integration of Artificial Intelligence for Predictive Glycemic Analytics is fundamentally altering clinical strategies by allowing for the identification of DKA risk factors hours prior to metabolic decompensation. Advanced algorithms within insulin management ecosystems now examine historical glycemic trends to forecast severe hyperglycemic events, generating alerts that trigger preemptive insulin or fluid administration to stabilize patient physiology. This shift toward intelligent, data-driven disease management is hastening the adoption of smart diabetes technologies; according to Medtronic's 'Second Quarter Fiscal Year 2025 Financial Results' from November 2024, diabetes segment revenue increased by 12.4% to USD 686 million, highlighting the market's shift toward algorithm-enhanced predictive systems.

Key Market Players

  • Novo Nordisk AS
  • Baxter Healthcare Corporation
  • B. Braun Medical Inc.
  • ICU Medical, Inc.
  • Pfizer Inc.
  • Merit Pharmaceutical
  • SteriCare Solutions
  • Soxa Formulations & Research (Pvt.) Ltd
  • BD company
  • Fresenius Kabi USA LLC

Report Scope

In this report, the Global Diabetic Ketoacidosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetic Ketoacidosis Market, By Treatment

  • Insulin Therapy
  • Electrolyte Replacement
  • Fluid Replacement

Diabetic Ketoacidosis Market, By End User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Diabetic Ketoacidosis Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Ketoacidosis Market.

Available Customizations:

Global Diabetic Ketoacidosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Diabetic Ketoacidosis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Insulin Therapy, Electrolyte Replacement, Fluid Replacement)
    • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Diabetic Ketoacidosis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Diabetic Ketoacidosis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Diabetic Ketoacidosis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Diabetic Ketoacidosis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By End User

7. Europe Diabetic Ketoacidosis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Diabetic Ketoacidosis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By End User
    • 7.3.2. France Diabetic Ketoacidosis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Diabetic Ketoacidosis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Diabetic Ketoacidosis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Diabetic Ketoacidosis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By End User

8. Asia Pacific Diabetic Ketoacidosis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Diabetic Ketoacidosis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By End User
    • 8.3.2. India Diabetic Ketoacidosis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Diabetic Ketoacidosis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Diabetic Ketoacidosis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Diabetic Ketoacidosis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By End User

9. Middle East & Africa Diabetic Ketoacidosis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Diabetic Ketoacidosis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Diabetic Ketoacidosis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Diabetic Ketoacidosis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By End User

10. South America Diabetic Ketoacidosis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Diabetic Ketoacidosis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Diabetic Ketoacidosis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Diabetic Ketoacidosis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Diabetic Ketoacidosis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novo Nordisk AS
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Baxter Healthcare Corporation
  • 15.3. B. Braun Medical Inc.
  • 15.4. ICU Medical, Inc.
  • 15.5. Pfizer Inc.
  • 15.6. Merit Pharmaceutical
  • 15.7. SteriCare Solutions
  • 15.8. Soxa Formulations & Research (Pvt.) Ltd
  • 15.9. BD company
  • 15.10. Fresenius Kabi USA LLC

16. Strategic Recommendations

17. About Us & Disclaimer